Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 19/20 | 0.93 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517787 | 1.00 | CASR (0.93) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL5515067 | 1.00 | CASR (0.93) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL5524824 | 1.00 | CASR (0.93) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL5519297 | 0.96 | CASR (1.00) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL5654746 | 0.90 | CASR (0.76) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL14522258 | 0.88 | CASR (0.73) | CASRHTT | |
| SCHEMBL5511591 | 0.87 | CASR (0.74) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL5521379 | 0.86 | CASR (0.72) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL5509062 | 0.86 | CASR (0.72) | CASRADRB2ADRB3CYP2D6SLC6A2 | |
| SCHEMBL5524136 | 0.86 | CASR (0.76) | CASRADRB2ADRB3CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-7202261-B2 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202261-B2 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202261-B2 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-0901459-B1 | CALCILYTIC COMPOUNDS | NPS PHARMA INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050032850-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| US-6818660-B2 | FOR INHIBITING CALCIUM RECEPTOR ACTIVIT; TO STIMULATE SECRETION OF PARATHYROID HORMONE (PTH); FOR BONE FORMATION | NPS PHARMACEUTICALS, INC. | 2004-11-16 | — | — | US | disclosed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6432656-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020099220-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-07-25 | — | — | US | disclosed |
| US-6022894-A | Method of using calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0901459-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997037967-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032850-A1 | Calcilytic compounds | CALCR, CASR, ORAI1 | CASR 2/4885ADRB2 482/4885ADRB3 1213/4885 |
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | CALCR, CASR, ORAI1 | CASR 2/4885ADRB2 482/4885ADRB3 1213/4885 |
| US-20020099220-A1 | Calcilytic compounds | CALCR, CASR, CALCRL | CASR 2/4885ADRB2 701/4885ADRB3 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.